Brandenburg, Vincent M.

Interrelated aldosterone and parathyroid hormone mutually modify cardiovascular mortality risk

Tomaschitz, A., Pilz, S., Rus-Machan, J., Meinitzer, A., Brandenburg, V. M., Scharnagl, H., Kapl, M., Grammer, T., Ritz, E., Horina, J. H., et al. (2015) · International Journal of Cardiology

Hormonal Regulation and HypertensionParathyroid Disorders and Treatments

Cited by 27

Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerenone in primary hyperparathyroidism trial

Verheyen, N., Fahrleitner-Pammer, A., Pieske, B., Meinitzer, A., Belyavskiy, E., Wetzel, J., Gaksch, M., Grübler, M. R., Catena, C., Sechi, L. A., et al. (2016) · Journal of Hypertension

Parathyroid Disorders and TreatmentsHormonal Regulation and Hypertension

Cited by 24

Plasma parathyroid hormone and cardiovascular disease in treatment‐naive patients with primary hyperparathyroidism: The EPATH trial

Wetzel, J., Pilz, S., Grübler, M. R., Fahrleitner‐Pammer, A., Dimai, H. P., von Lewinski, D., Kolesnik, E., Perl, S., Trummer, C., Schwetz, V., et al. (2017) · The Journal of Clinical Hypertension

Parathyroid Disorders and TreatmentsHormonal Regulation and Hypertension

Cited by 22

The uses and abuses of Vitamin D compounds in chronic kidney disease-mineral bone disease (CKD-MBD)

Goldsmith, D. J. A., Massy, Z. A., & Brandenburg, V. (2014) · Seminars in Nephrology

Parathyroid Disorders and TreatmentsVitamin D Research Studies

Cited by 21